Heart Test Laboratories Inc. Common Stock (HSCS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heart Test Laboratories Inc. Common Stock (HSCS) has a cash flow conversion efficiency ratio of 648.679x as of July 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.32 Billion) by net assets ($-2.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HSCS market cap for the company's overall valuation and market capitalisation.
Heart Test Laboratories Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2026)
This chart illustrates how Heart Test Laboratories Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Heart Test Laboratories Inc. Common Stoc share price for real-time trading data and today's change.
Heart Test Laboratories Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heart Test Laboratories Inc. Common Stock ranked by their cash flow conversion efficiency. Review Heart Test Laboratories Inc. Common Stoc (HSCS) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FN Factory Outlet Public Company Limited
BK:FN
|
-0.024x |
|
Innodep Inc.
KQ:303530
|
-0.187x |
|
Solid Automotive Bhd
KLSE:5242
|
0.007x |
|
Draper Esprit PLC
LSE:GROW
|
0.024x |
|
Horizon Petroleum Ltd
V:HPL
|
0.257x |
|
INOVIQ LTD.
F:EGQ0
|
N/A |
|
Dantax
CO:DANT
|
-0.091x |
|
Yuyu Pharma Inc
KO:000225
|
0.034x |
Annual Cash Flow Conversion Efficiency for Heart Test Laboratories Inc. Common Stock (2020–2026)
The table below shows the annual cash flow conversion efficiency of Heart Test Laboratories Inc. Common Stock from 2020 to 2026. Also see total assets of Heart Test Laboratories Inc. Common Stoc for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-04-30 | $226.06 Million | $-7.43 Million | -0.033x | +99.91% |
| 2025-04-30 | $205.17K | $-7.41 Million | -36.131x | -4255.39% |
| 2024-04-30 | $7.32 Million | $-6.07 Million | -0.830x | +96.69% |
| 2023-04-30 | $230.56K | $-5.77 Million | -25.042x | -4261.43% |
| 2022-04-30 | $-6.06 Million | $-3.64 Million | 0.602x | -53.14% |
| 2021-04-30 | $-1.91 Million | $-2.45 Million | 1.284x | +110.55% |
| 2020-04-30 | $315.55K | $-3.84 Million | -12.169x | -- |
About Heart Test Laboratories Inc. Common Stock
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related… Read more